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Abstract: Type 2 diabetes (T2D) is a chronic metabolic disorder resulting from genetic and environmental factors that 
bring about tissue desensitization to insulin and consequent hyperglycemia. Despite strict glycemic control and the fact 
that new and more effective antidiabetic drugs are continuously appearing on the market, diabetic patients still suffer 
from the disease and its complications. Recent findings present a strong link between diabetes, inflammation, altered gut 
microbiota and bile acid (BA) disturbances. BAs are naturally produced in humans and are gaining an appreciable 
interest as an adjunct treatment for T2D due to their endocrine signalling and anti-inflammatory properties. However a 
significant limitation to their efficacy is their low oral absorption, poor targeted delivery, gut metabolism and inter- and 
intra-individual dose variations. Thus there is a need for a novel and robust formulation that will encapsulate the BAs and 
protect them until they reach the lower intestine allowing them to be clinically beneficial. Artificial Cell Microencapsulation 
(ACM) is a novel oral delivery system for biologically active molecules and has been used significantly in the delivery of 
various cells and therapeutics. ACM-BA formulation has the potential to optimise BA efficacy and safety profiles and may 
have a place in the treatment of diabetes. This review aims to investigate the applications of BAs in T2D and the use of 
ACM as a novel delivery system for their optimum delivery.  
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INTRODUCTION 
Diabetes Mellitus 
Diabetes Mellitus is a polygenic disorder indicative 
of multiple aetiologies of which type 1 and type 2 are 
the most common subgroups [1, 2]. Type 1 diabetes 
(T1D) is an autoimmune disease that develops upon 
the destruction of the pancreatic -cells, thus resulting 
in a total lack of insulin production and uncontrolled 
glucose homeostasis [3]. Conversely, T2D is caused by 
both genetic and environmental factors and is 
characterized by a poor response to insulin such that 
insulin is no longer able to stimulate the uptake of 
glucose into peripheral tissues such as fat and muscle, 
hence leading to insulin resistance [3]. Both diabetic 
forms have prominent disturbances of the gut with 
altered BA pools, which can significantly impact on the 
drug therapies available, potentially altering their 
absorption [4]. This review will focus on such 
alterations specific to T2D. 
Type 2 Diabetes 
T2D is becoming an increasing epidemiological 
problem of the 21
st
 century with approximately 346 
million people suffering with this disease worldwide [1, 
5]. Such a metabolic disorder will continue to increase 
in prevalence due to environmental factors including  
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Western diet, obesity and sedentary lifestyles [1, 5]. 
Alongside environmental factors, genetic factors can 
also result in dysregulation of glucose metabolism 
mediated via glucose transporter type 4 (GLUT4) [6, 7]. 
GLUT4, a protein transporter located in adipose and 
muscle tissues, is defective in the transport of insulin in 
diabetic patients, resulting in a constant hypergly-
caemic state [6, 7]. This -cell failure and insulin 
resistance has been associated with BA imbalances 
and chronic inflammation [8, 9].  
Current therapies aimed at treating T2D focus on 
ameliorating hyperglyceamia via enhanced insulin 
production (e.g. sulphonylureas) or improving insulin 
sensitivity (e.g. metformin) [2, 10, 11]. However there 
are limitations to such therapies as they fail to address 
the dysbiosis, BA dysregulation and inflammation 
which all perpetuate the hyperglycemic state and 
pancreatic cell damage [2, 12]. As a direct result of 
these inflammatory processes and physiological 
disturbances, T2D complications such as cardio-
vascular disease, metabolic disturbances and tissue 
necrosis still remain largely inevitable unless the 
underlying causes of inflammation, dysbiosis and BA 
disturbances are properly addressed [13, 14].  
With continuous overstimulation of the -cells in the 
pancreas from anti-diabetic drug therapy and chronic 
hyperglycemia, tissue exhaustion and subsequent 
destruction of the -cells occurs which may lead to 
complete lack of insulin production, mimicking T1D 
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(many T2D patients eventually revert to insulin therapy) 
[4]. 
METHODOLOGY 
The aim of this review was to examine the literature 
on the effects BAs instigate on pancreatic -cells using 
a novel technique of oral delivery. 
Initially, several databases and various search 
engines were analyzed using the primary outcome 
measures (key words used in the literature search 
strategy) deemed most relevant to the topic and 
included type 2 diabetes, glucose homeostasis, insulin 
resistance, inflammation, obesity, diet and gut 
disturbances. The search strategy was limited to the 
English language and filtered for articles published post 
year 2000.  
In total 122 potentially relevant articles were found. 
Narrowing the search down via secondary outcome 
measures which included BAs, enterohepatic recir-
culation, homeostasis and microencapsulation resulted 
in a total of 78 publications being incorporated for the 
purpose of this review.  
Figure 1 below details the process in which the 
primary and secondary outcomes were obtained.  
Search engines utilized for the purpose of this 
review were as follows: PubMed, ProQuest, IPA, Google 
scholars, Science Direct, Embase and SciFinder. 
T2D: AN INFLAMMATORY DISEASE 
GIT Disturbances 
The gastrointestinal tract (GIT) microflora greatly 
contributes to energy balance and limits the access of 
pathogenic bacteria [15, 16]. The concentration of 
bacteria varies greatly along the GIT with low 
concentrations in the stomach and duodenum (10-10
3 
colony forming units (cfu/ml) and increasing levels in 
the colon (10
11-12
cfu/ml) [17, 18]. The microbial 
composition in the GIT harbours two main phyla; 
Lactobacillus and Bifidobacteria, while the colon 
represents mainly Bacteroidetes [17, 19]. In T2D, there 
is an alteration in the GIT flora with experimental 
studies of obese rats and humans revealing a 50% 
reduction of Bacteroidetes in the colon and an increase 
in Firmicutes proportionally [17, 20]. Interestingly, 
dietary modifications consisting of reduced caloric 
intakes of saturated fats and carbohydrates result in 
increasing levels of beneficial bacteria along the GIT 
(i.e. the less the intake, the greater the levels of 
beneficial microbiota) [17].  
Dysbiosis (a term used to describe alterations and 
imbalances in the gastrointestinal microbial environ-
ment) arising from high fat diets in numerous animal 
studies has been shown to result in increased gut 
permeability with reduced protein expressions of ZO-1 
and occludens [21]. The resulting reduction leads to a 
loss of beneficial bacteria to harmful strains and an 
activation of the innate immune system (via 
lipopolysaccharide (LPS) induced endotoxaemia) [21]. 
The resulting inflammatory burden perpetuates -cell 
loss, insulin resistance and various metabolic sequelae 
(i.e. increased obesity and hepatic lipid accumulation) 
[21]. It is worth noting that the translocation of bacteria 
from diabetic to germ free mice under laboratory 
conditions results in profound hyperglyceamia 
mimicking the diabetic state [21-23]. 
The relationship interconnecting obesity, diet and 
inflammation to pathophysiological disturbances in 
 
Figure 1: Literature search process. 
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diabetes concerning the various organs discussed 
herein is depicted in Figure 2.  
Recently, it has become evident that inflammation 
plays a pivotal role in the development and progression 
of T2D [24]. As illustrated in Figure 2, inflammation 
results from high fat diet and obesity which ultimately 
leads to an alteration of the gut epithelium and also 
results in widespread systemic inflammation affecting 
various organs including but not limited to the 
pancreas, muscle, liver and adipose tissue. This 
inflammatory cascade has been closely associated with 
tissue insensitivity to drugs, increasing levels of 
circulating reactive radicals and poor enterohepatic 
recirculation which cumulatively manifest as inadeq-
uate response by tissues to administered therapeutics, 
creating a cycle of add-on therapies and polypharmacy 
[15]. Thus it is necessary to investigate the underlying 
causes to the development of this inflammation which 
is the hallmark in the development and progression of 
T2D and its multiorgan complications [25]. Failure to 
properly appreciate, understand and target the 
inflammation of diabetes will result in worsening 
disease outcome and ineffective, suboptimal 
polypharmacy. Factors attributed to the inflammatory 
burden associated with T2D are many and varied but 
predominately include obesity, high fat diet and gut 
disturbances [26].  
Obesity 
A large body of evidence is suggesting that there is 
a strong correlation between T2D and obesity, 
characterised by a low-grade inflammation with an 
unknown molecular origin [22, 27]. In both diet induced 
and transgenic models of T2D, the enlargement of 
adipose tissue results in high levels of pro-inflammatory 
cytokines due to enhanced macrophage activity [25]. 
These mediators include but are not limited to C 
reactive protein, (CRP) interleukin 1 (IL-1), interleukin 6 
(IL-6) and Tumor Necrosis Factor  (TNF ) which 
further result in -cell damage, increased insulin 
resistance and greater lipid accumulation by the liver 
and adipose tissue [27-29].  
This inflammation associated enlargement of 
adipose tissue in diabetic animals is also capable of 
altering the natural microbiota of the GIT, which under 
healthy conditions would play an essential role in 
harvesting energy from the diet and increasing 
lipogenesis (through the expression of enzymes such 
as acetyl coA carboxylase and fatty acid synthase) 
[20]. A proposed cause for this alteration in the GIT 
involves the activation of LPS (derived from a Gram 
negative bacteria) that is present in the GIT and is 
capable of triggering the secretion of pro-inflammatory 
cytokines, hence leading to liver insulin resistance, 
adipose tissue macrophage infiltration and hyperinsu-
linaemia [20, 22, 27].  
The underlying cause to the development of T2D in 
conjunction with obesity, is high fat concentrations with 
circulating free fatty acids (due to increased lipid 
intakes), leading to a state known as endotoxaemia 
which is defined as the accumulation of toxic metabolic 
by-products (end products of oxidative stress) capable 
of stimulating the immune system and worsening the 
inflammatory burden [20]. With continued exposure to 
high glucose and non-esterified fatty acids (NEFA) that 
 
Figure 2: Inflammation as the hallmark of pathological disturbances affecting multiple organs. 
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are stored in adipose tissue, pancreatic -cells become 
desensitized, leading to a reduction in glucose-
stimulated insulin secretion and -cell mass, eventually 
resulting in apoptosis [30]. This can be explained in 
terms of NEFA’s slowing down metabolism, glucose 
uptake and oxidation [30]. As a consequence of this 
oxidation, glucose metabolism becomes impaired with 
the generation of free radicals, further enhancing 
inflammation and the progression of T2D [30]. In 
addition to high fat diets, high carbohydrate based diets 
have also been shown to negatively impact the 
glycaemic control in T2D [24]. Conversely, a low 
carbohydrate diet can significantly improve glycaemic 
control and reduce body weight, the latter being an 
important risk factor for the development and 
progression of T2D and its complications [24]. 
The relationship between high fat feeding in animal 
studies and an alteration in the gut microbiota has also 
demonstrated the imbalance between gram negative to 
gram positive bacteria [21]. This phenomenon, termed 
dysbiosis, leads to elevations of LPS levels creating a 
state of endotoxaemia characterized by enhanced 
macrophage activity and the release of pro-
inflammatory cytokines [17]. Owing to poor antioxidant 
defense mechanisms of the pancreatic -cells, this 
inflammatory burden leads to gradual -cell failure and 
worsening hyperglyceamia with subsequent insulin 
resistance and worsening obesity [17]. 
Oxidative Stress 
In T2D, pancreatic -cell dysfunction occurs due to 
oxidative stress, which has the potential to initiate 
tissue damage [31]. This oxidative stress originates 
from the inflammatory burden of dysbiosis, lipid 
peroxidation and BA disturbances [21]. Probucol, an 
anti-hyperlipidaemic agent, has been shown to 
preserve -cell function and mass via potent 
antioxidant effects, resulting in an indirect improvement 
in the primary end points of glucose and insulin levels 
[9]. 
Probucol’s profound effects in diabetes are further 
confirmation that oxidation from radical oxygen species 
(ROS) play a crucial role in diabetes induction and 
development. It is well known that the pancreas has 
very little antioxidant defense mechanisms, thus 
portraying its vulnerability to oxidative damage [32]. 
Mechanistically, probucol’s high lipophilicity and strong 
radical scavenging effects (double aromatic rings in the 
chemical structure) allow cellular penetration and 
 
Figure 3: Low grade inflammation impacting various organs. 
Potentials and Limitations of Bile Acids in Type 2 Diabetes Journal of Endocrinology and Diabetes Mellitus, 2013, Vol. 1, No. 2      53 
reductions in ROS of pancreatic islets [31, 32]. 
Probucol has also been shown to decrease thioredoxin 
interacting protein (TXNIP) expression, compensated 
by increases in thioredoxin (TRX) expression [31]. This 
allows the reduction of oxidative stress via 
enhancements in the -cell’s cellular redox status [31]. 
Bile Acids 
BA synthesis from cholesterol is the primary 
pathway involved in the catabolism of cholesterol [13]. 
The synthesis of BA is a complex, highly regulated 
process constituting multistep and multi-organelle 
processes [11, 13, 33].  
BAs are amphipathic molecules that are produced 
in the liver and secreted into bile [34]. In the liver, 75% 
of the BA synthesis occurs via the oxidation of 
cholesterol through a major enzyme known as CYP7A1 
[35, 36]. The end product of this pathway results in the 
formation of two principal BAs in humans; namely 
cholic acid (CA) and chenodeoxycholic acid (CDA) [37, 
38]. In the intestinal lumen, particularly in the colon, 
primary BAs are converted into secondary BAs known 
as deoxycholic acid (DCA) and lithocholic acid (LCA) 
via GIT microflora biochemical modifications namely 
deconjugation, oxidation and dehydroxylation [11, 33, 
35]. Before the excretion of BA from the hepatocytes, 
they are conjugated to either taurine (mice) or glycine 
(humans) which ultimately converts them into more 
hydrophilic, zwitterionic compounds at physiological pH 
via the reduction of their pka [39]. These fully ionized 
species are now termed bile salts, which are highly 
effective detergents involved in lipid absorption due to 
micelle formations in the small intestine owing to their 
enhanced, beneficial amphoteric nature [4, 11, 33].  
The BA pool of a human and mice differ in 
composition, with hydrophilic BAs muricholic acid 
(MCA) and CA predominating in mice and the more 
hydrophobic BAs CDA, CA and DCA predominating in 
humans [36, 40]. Importantly rats do not contain a gall 
bladder so cannot store BAs as such, rather bile is 
instantaneously made via a post-prandial mechanism 
after ingestion of a meal [4]. This has important 
ramifications in the extrapolation of animal studies 
concerning BAs to the human population.  
In addition to dietary lipid absorption and cholesterol 
metabolism, BAs play a significant physiological role 
which includes functioning as potent signaling 
molecules and interestingly several BA signaling 
pathways have recently been identified [13, 41]. Thus, 
BAs encompass crucial multi-organ functions and are 
vital for the body’s overall homeostasis. They have 
pivotal roles in the modulation of the immune system 
(via their anti-inflammatory effects resulting in the down 
regulation of the synthesis of pro-inflammatory 
cytokines such as TNF-  from monocytes and 
macrophages through nuclear factor kappa-light-chain-
enhancer of activated B cells (NF- B) inhibition), 
energy balance (BA receptors regulate glucose and 
lipid metabolism and energy expenditure) as well as 
key roles in dietary absorption of lipids previously 
alluded to [2, 13, 39, 41].  
Enterohepatic Circulation 
After the ingestion of a meal, bile flows into the 
duodenum aiding the solubilisation of dietary lipids and 
their digestion [11, 33]. However, the BA pool is 
recycled via a complex system interconnecting the liver 
and intestine [2, 13, 39, 41]. BAs are reabsorbed via a 
combination of passive diffusion and active transport 
from the terminal ileum and transported back to the 
liver via the portal vein [42-44]. This process is termed 
enterohepatic circulation and constitutes an essential 
role in maintaining a constant BA pool as BAs are toxic 
to tissues at high concentrations [2, 13, 39, 41]. The 
enterohepatic circulation process occurs approximately 
twelve times a day with high efficiency of 95% [42-44].  
BA homeostasis is tightly regulated by the intestinal 
microbiota which play a crucial role in the biochemical 
modifications of the BAs (deconjugation, epimerization 
and oxidation) [45]. Such modifications are pivotal for 
BA reabsorption and their hydrophobic properties [45]. 
Of all the biochemical modifications by the gut 
microbiota, deconjugation is the primary catabolic step 
required for BA enterohepatic circulation [43]. Many 
bacteria located in the GIT are capable of 
deconjugating BA especially Lactobacillus and 
Bifidobacteria [13, 45-47].  
In T2D, the dysbiosis in the gut results in the 
reduction of levels of beneficial bacteria (Lactobacillus 
and Bifidobacteria) which are replaced by pro-
inflammatory strains such as Bacteroides [48]. This 
reduction in Lactobacillus contributes to an overall net 
pool of toxic conjugated BAs and their accumulation as 
described in T2D has been associated with further 
inflammatory damage to the pancreas and other 
organs [46]. Hence, the accumulation of these 
secondary BAs perpetuates the already widespread 
inflammation noted in T2D, compromising glycaemic 
and metabolic dysregulation even further [46].  
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Additionally, T2D has been associated with a 
disruption in the enterohepatic circulation of BAs and a 
higher rate of total BA synthesis [49]. This results in 
enhanced CA synthesis and subsequent conversion to 
DCA [49]. Thus, reductions of beneficial Bifidobacteria 
species as is noted in T2D lead to an increase in 
intestinal endotoxin levels that participate in low-grade 
inflammation and decrease the mucosal barrier 
function [20].  
BAs, as previously described, are potent signaling 
molecules with multiorgan functions throughout the 
body [11, 33]. There are two prominent receptors 
responsible for BA signaling pathways, farnesoid X 
receptor (FXR) and the G-protein coupled membrane 
receptor TGR5 [11, 33]. Both these pathways are 
discussed herein, but it should be stressed that 
receptor independent pathways of cell signaling 
networks (such as the mitogen-activated protein kinase 
pathway) can also be activated by BAs, the scope of 
which is beyond this review [13].  
The nuclear receptor FXR is primarily expressed in 
the liver and intestine; principle sites of BA 
biosynthesis, metabolism and enterohepatic cycling 
[50]. However, it has also been noted in the pancreas 
and adipose tissue and plays a central role in the 
body’s energy balance [13, 35]. 
The activation of intestinal FXR by absorbed BA in 
the terminal ileum results in the expression of 
enterocytic fibroblast growth factor 19 (FGF-19, and 
FGF-15 in mice) [13]. BAs returning from the 
enterohepatic recirculation in the liver also stimulate 
FGF-19, which binds to its receptor complex FGF 
receptor 4 (FGFR4) on nearby hepatocytes [13]. This 
signaling interaction between FGF-19 and FGFR4 
results in the inhibition of CYP7A1 via the c-Jun N-
terminal kinase (JNK)-mediated pathway, avoiding the 
accumulation of excessive BA that are hepatotoxic [51]. 
In addition to the induction of FGF-19, basolateral 
transporters such as organic solute transporter alpha 
and beta (OSTa, OSTb) are essential in the transport 
of BA into the portal vein [52].  
An increase in BA pool size results in negative 
feedback mechanisms governed by nuclear receptors 
that will suppress the transcription of CYP7A1 (involved 
in BA synthesis) and CYP8B1 (which controls the 
production of CA) [53]. As BAs reach a significant level 
in the liver, FXRa induces the expression of the small 
heterodimer partner, (SHP) which inhibits the activity of 
nuclear factor 4a (NR2A1/ HNFa) and liver receptor 
homolog-1 (NRGA2/LRH-1) in the hepatocyte [36, 53]. 
The repression of these transcription factors and 
CYP7A1 results in the suppression of BA synthesis and 
therefore accumulation of BAs [36]. Both LRH-1 and 
HNF-4a are regulated by CYP8B1 which is an 
important modulator of BA pool size and composition 
[36, 54]. BAs have also been shown to activate FXR-
independent signaling pathways to repress CYP7A1 
gene expression [11]. Specifically, it has been shown 
that feeding FXR knockout mice a cholic acid diet still 
results in CYP7A1 repression independent of the FXR 
or SHP pathways [11]. These findings suggest that 
super-physiological levels of BAs result in redundant 
pathways being activated to repress BA synthesis and 
restore the BA pool size [11].  
It is important to appreciate that the expression of 
several key transporters are altered in T2D. For 
example, the expression of mammalian transporters 
multidrug resistance-associated protein (MRP) 2, MRP 
3 and MRP 4 located in the liver and renal tubules are 
altered resulting in the accumulation of toxic BAs [55-
57]. Additionally, it has been shown via recent animal 
studies that T2D also alters the expression of ABC 
transporters and the FXR receptor, resulting in 
disturbances to the BA pool and manifesting in 
worsening inflammation, hyperglycemia and obesity [4, 
11, 13, 33, 41]. Data from human studies showed that 
T2D patients have an increase in BA pool size and 
fecal BA excretion that can be decreased via insulin 
therapy [13]. Subsequently, animal studies revealed 
that insulin inhibits CYP7A1 and CYP27A1 expression 
in rat hepatocytes, enzymes involved in BA synthesis 
[13]. The dysbiosis noted in the gut of diabetic patients 
also has adverse metabolic sequelae; with pro-
inflammatory bacterial strains converting cholic acid to 
deoxycholic acid, a potent toxic BA contributing to local 
inflammation and tissue necrosis [13].  
Energy Expenditure 
It is now well documented that BAs regulate hepatic 
glucose metabolism via the FXR-mediated pathways 
[35]. These metabolic regulatory pathways are involved 
in hepatic glucose production, hepatic lipoprotein and 
cholesterol mechanism, lipogenesis, insulin sensitivity 
and adipocyte functions and muscle energy 
expenditure [11].  
Additionally, it has recently been discovered that the 
BA receptor, TGR5 (a G-protein coupled receptor) also 
plays a key role in the body’s energy balance and it is 
expressed in the GIT, skeletal muscle, adipose tissue 
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and immune cells as illustrated in Figure 4 [36]. TGR5 
mediated signaling pathways are particularly involved 
in muscle energy expenditure and intestinal GLP-1 
secretion [36].  
Upon BA activation, TGR5 leads to an induced 
intracellular cAMP production, converting thyroxine 
(T4) into the active T3, thus causing weight loss via 
enhanced energy expenditure [11]. 
In addition, TGR5 is also involved in 
immunoregulatory properties of BA [35]. TGR5 is very 
relevant to BA metabolism as chronic inflammation is 
now known to contribute to the metabolic dysfunction 
evident in T2D [36]. BAs capable of TGR5 activation 
were found to increase cAMP in alveolar macrophages 
which inhibited LPS induced pro-inflammatory 
cytokines TNFa, IL-1, 6 and 8 [36]. TGR5’s anti-
inflammatory effects are therefore useful for protecting 
the liver against lipid peroxidation and injury induced by 
BAs [36]. The identification of these pathways provides 
the definitive proof of BAs role in immunosuppression, 
glucose homeostasis and energy balance [36].  
Furthermore, FXR expression itself is reduced in rat 
models of T2D. In its absence, mice showed an 
increased level of inflammation, (induced by LPS) 
insulin resistance and hyperglycemia [35, 42]. 
Furthermore they developed pro-inflammatory and pro-
fibrotic phenotypes in the intestine, leading to bacterial 
overgrowth and exacerbated colitis [50]. Therefore the 
prospective for BA as a potential source for the 
treatment of diabetes stems from the idea that BAs 
inhibit the macrophage release of LPS-induced pro-
inflammatory cytokines and therefore play an 
immunosuppressive effect [42]. Given that 
inflammation appears to be an important “cause and 
effect” mediator in T2D, the potential anti-inflammatory 
and immunosuppressive effects of BAs as 
biotherapeutic adjuncts in the therapy of diabetes hold 
great promise. The concern is how to best deliver such 
potent yet labile agents; fortunately artificial cell 
microencapsulation offers such an avenue, as 
discussed below.  
ARTIFICIAL CELL MICROENCAPSULATION 
Biodegradable polymers have been the major focus 
to developing efficacious delivery systems for 
pharmaceutical research [58, 59]. Therefore 
microencapsulation is a novel technique that can be 
useful in terms of protecting a labile drug or as a 
means to control drug release [60]. This method aims 
to envelope solids or liquids into a capsule as a means 
to isolate the inside from the host immune system and 
 
Figure 4: The physiological roles of bile acids. 
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environment [61, 62]. However at the same time, once 
it reaches the site of action, allows the exchange of 
nutrients and waste; thus releasing the encapsulated 
ingredients in a sustained, constant manner (zero-order 
release of contents at the site of action) [63]. 
Furthermore, the semipermeable membrane 
prevents antibodies, immunologic moieties and high 
molecular weight molecules from destroying the 
encapsulated material as foreign invaders [64]. Ideally 
the system should achieve an effective concentration of 
the material entrapped at the site of action for an 
extended period of time, whilst minimizing systemic 
exposure [63]. As a consequence, artificial cell 
microencapsulation is gaining favour in providing a 
constant drug delivery system (with zero order kinetics 
of drug release) at an affordable cost [64]. This zero 
order drug release is made possible using several 
polymers such as alginate and provides an advantage 
over conventional oral delivery which would otherwise 
have erratic rise and fall in plasma concentrations, 
rendering many therapies suboptimal or even 
ineffective. For the drug encapsulated inside the 
capsule to be released at the targeted site of action, it 
must undergo several steps [65]. Firstly, the outer layer 
absorbs water resulting in swelling of the microcapsule 
and gradual loss of bead surface integrity, making the 
outer surface more porous. This is followed by erosion 
which involves the breakdown of the porous outer layer 
(due to dissolution of the alginate matrix at alkaline pH) 
resulting in zero order kinetics whereby diffusion of the 
encapsulated material occurs in a time independent 
manner [58]. Thus it has been shown and is well 
documented in the literature that at adequate alginate 
concentrations and optimal viscosity, microcapsules 
containing alginate can at the desired site of action 
release encapsulated drugs in a zero order manner 
due to an equilibrium in swelling and erosion at alkaline 
pH, resulting in a constant diffusion taking place 
whereby the drug is liberated and achieves steady 
concentrations at the site (with no fluctuations) 
independent of time or the drug’s half-life [58, 65, 66]. 
This technique could be a potential avenue for the 
delivery of BAs such as deoxycholic acid, into the 
colon, by promoting a sustained release system so that 
the BA can act as an anti-inflammatory agent and aid in 
the treatment of T2D [61]. A recent interest in providing 
a sustained release formulation was conducted on the 
sulphonylurea gliclazide [67]. This oral hypoglycemic 
agent has an unpredictable and highly varied 
absorption from the gastrointestinal tract partly due to 
the poor dissolution of drug from the formulation and 
poor permeability across the GI membrane [59]. A 
more effective drug delivery system was attained 
following microencapsulation of gliclazide, which 
displayed enhanced in-vitro and in-vivo characteristics 
compared to conventional delivery [67].
 
Throughout the literature there are several 
commonly used polymers as coating materials required 
for encapsulation including sodium alginate (SA), 
pectin, chitosan and methylcellulose with majority of 
studies employing sodium alginate [64, 68, 69]. This 
polymer has gained high popularity due to its 
favourable properties such as high stability, non-
toxicity, solubility and excellent biocompatibility and 
biodegradability [12, 64, 70]. 
SA is the salt of alginic acid, which is a natural 
polysaccharide derived from seaweed that consists of 
two sugars known as D-mannuronate and L-guluronate 
[71, 72]. SA has well established pH-release kinetics 
and is significantly influenced by the viscosity of its 
matrix [73]. Recent studies have demonstrated a faster 
and well controlled drug release from the low viscosity 
SA (LVSA) compared with high viscosity (HVSA) 
suggesting more superior performance when targeting 
distal sites of the GIT such as the cecum [74]. In gastric 
fluid, the hydrated LVSA is converted into a porous, 
insoluble structure, called an alginic acid matrix [58]. 
The combination of hydrophilic alginate with calcium 
chloride is commonly employed to form a calcium-
alginate system (calcium alginate beads sized 300-
800um diameters) due to its easiness in gel formation 
[75, 76]. The production technique used to prepare the 
polyelectrolye complex gel includes the vibration nozzle 
method (VNM) [60, 77].  
This technique deploys vibration, which causes a 
break up of laminar liquid resulting in equally sized 
droplets, at a selected frequency (higher frequency 
produces smaller beads). The formation of these 
spherical droplets occurs due to surface tension [71]. 
Parameters involved in the droplet formation via the 
VNM technique includes vibration frequency, electrode 
tension, nozzle size and jet flow rate [60]. This novel 
and promising technique is effectively utilized to 
produce homogeneous and stable beads using the 
Buchi-B390 Encapsulator (Buchi Instruments, 
Switzerland) equipped with various nozzle sizes [60]. 
However, the VNM methodology is not without its 
limitations. This method does not entail high production 
yields as only a single droplet forms after another at 
any given time. Adjusting the production flow rate with 
Potentials and Limitations of Bile Acids in Type 2 Diabetes Journal of Endocrinology and Diabetes Mellitus, 2013, Vol. 1, No. 2      57 
increasing diameters or increasing vibration frequency 
results in greater production volumes and represents a 
way of balancing production yields with beads size 
control [60, 71].  
CONCLUSION 
Throughout this literature review, it is evident that 
the underlying cause of developing insulin resistance 
and therefore T2D is inflammation (beginning with low-
grade inflammation that precedes widespread systemic 
inflammation and oxidative stress evident in overt 
hyperglycaemia and chronic T2D). There are several 
factors that contribute to this low-grade inflammation 
including obesity, high fat diets and a change in gut 
microflora. This inflammatory cascade results in major 
changes in the gut, which in turn initiates an alteration 
in the bile flow and feedback mechanisms required for 
enterohepatic circulation. Therefore future diabetes 
therapy should not only focus on rectifying glucose 
imbalance but also in targeting the disturbances in BA 
composition and the inflammation cascade initiated in 
the gut. This can be achieved by using small 
concentrations of BA (known to inhibit the growth of 
bacteria) to reach the colon as the site of action to 
normalize the composition of BAs and microflora, gut 
immune- response and microflora-epithelial interactions 
towards maintaining normal biochemical reactions and 
healthy body physiology [78]. A novel delivery system 
with promising results such as artificial cell 
microencapsulation could allow for targeted delivery of 
labile therapeutic agents such as BAs with sustained 
release kinetics, ensuring effective delivery to the gut to 
alleviate inflammation and provide a better means of 
improving glyceamic control in T2D as an adjunct to 
mainstream drug therapy.  
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